Table II.

Demographic characteristics and patient-reported outcomes of the participants by skin diseases

Group	N	Age, years	Women, %	PRO measures score (mean ± SD)
				Itch NRS	Pain NRS	PHQ-2	GAD-2	PSQI	Health utility
Healthy controls	14,642	18.4 ± 0.8	6614 (45.2)	1.00 ± 1.36	0.31 ± 0.79	0.74 ± 1.11	0.79 ± 1.12	3.64 ± 2.72	0.97 ± 0.07
Noncommunicable skin diseases∗	5563	18.3 ± 0.7	2527 (45.4)	1.56 ± 1.83	0.44 ± 1.02	0.86 ± 1.21	0.92 ± 1.20	4.12 ± 2.62	0.97 ± 0.07
Moderate to severe acne	2902	18.3 ± 0.8	1019 (35.1)	1.31 ± 1.60	0.39 ± 0.93	0.77 ± 1.13	0.82 ± 1.08	3.86 ± 2.62	0.97 ± 0.06
Eczema	1644	18.2 ± 0.7	876 (53.3)	2.13 ± 2.18	0.57 ± 1.23	1.10 ± 1.40	1.18 ± 1.36	4.71 ± 2.61	0.96 ± 0.12
Atopic dermatitis	910	18.2 ± 0.7	486 (53.4)	2.25 ± 2.3	0.52 ± 1.22	0.95 ± 1.25	1.02 ± 1.21	4.51 ± 2.53	0.97 ± 0.12
Chronic urticaria	716	18.2 ± 0.7	351 (49.0)	1.98 ± 2.07	0.45 ± 0.97	0.85 ± 1.21	0.94 ± 1.23	4.04 ± 2.88	0.97 ± 0.14
Chronic spontaneous urticaria	414	18.3 ± 0.7	220 (53.1)	2.07 ± 2.12	0.42 ± 0.89	0.93 ± 1.26	0.98 ± 1.25	4.23 ± 3.07	0.96 ± 0.14
Chronic inducible urticaria	302	18.3 ± 0.7	131 (43.4)	1.87 ± 2.01	0.49 ± 1.07	0.74 ± 1.14	0.89 ± 1.21	3.78 ± 2.58	0.96 ± 0.06
Psoriasis	45	18.4 ± 1.0	23 (51.1)	2.58 ± 2.74	1.02 ± 2.28	0.73 ± 1.12	1.00 ± 1.48	4.04 ± 2.66	0.97 ± 0.05
Vitiligo	64	18.4 ± 0.8	21 (32.8)	1.32 ± 1.96	0.46 ± 0.82	0.86 ± 1.21	0.89 ± 1.16	3.84 ± 2.92	0.97 ± 0.06
Rosacea	851	18.2 ± 0.7	554 (65.1)	1.32 ± 1.64	0.37 ± 0.90	0.90 ± 1.25	0.99 ± 1.23	4.33 ± 2.32	0.97 ± 0.06

GAD-2, Generalized Anxiety Disorder–2; NRS, numeric rating scale; PHQ, 2-item Patient Health Questionnaire; PRO, patient-reported outcome; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation.

^∗This is a combined group of all the conditions listed beneath it (as subsets).